Ticker League

Cash on Hand for Biogen (BIIB)

As of · Reported

Metric

Latest period

$4.28B

YoY change

+60.7%

5Y CAGR

+7.9%

Peak year (2016)

$4.90B

Cash on Hand history chart for Biogen (BIIB) from 1985 to 2025

Latest: $3.82B

Cash on Hand growth chart for Biogen (BIIB) from 1985 to 2025

Latest: +60.7%

Cash on Hand history table for Biogen (BIIB) from 1985 to 2025

  • 2025$3.82B+60.7%
  • 2024$2.38B+126.2%
  • 2023$1.05B-78.5%
  • 2022$4.89B+28.7%
  • 2021$3.80B+45.7%
  • 2020$2.61B-41.7%
  • 2019$4.48B+26.5%
  • 2018$3.54B-4.1%
  • 2017$3.69B-24.6%
  • 2016$4.90B+42.8%
  • 2015$3.43B+85.8%
  • 2014$1.85B+50.9%
  • 2013$1.22B-28.3%
  • 2012$1.71B+0.9%
  • 2011$1.69B+40.0%
  • 2010$1.21B-4.4%
  • 2009$1.26B-7.9%
  • 2008$1.37B+15.9%
  • 2007$1.18B+31.1%
  • 2006$902.69M+6.1%
  • 2005$850.75M-19.6%
  • 2004$1.06B+26.6%
  • 2003$835.96M-3.6%
  • 2002$867.11M+8.6%
  • 2001$798.11M+17.0%
  • 2000$682.41M+4.3%
  • 1999$654.54M+26.6%
  • 1998$516.91M+17.5%
  • 1997$440.09M+36.9%
  • 1996$321.38M+4.4%
  • 1995$307.95M+15.0%
  • 1994$267.80M+259.5%
  • 1993$74.50M-13.3%
  • 1992$85.90M+51.8%
  • 1991$56.60M+349.2%
  • 1990$12.60M-62.0%
  • 1989$33.20M-38.9%
  • 1988$54.30M-0.2%
  • 1987$54.40M-22.8%
  • 1986$70.50M+31.8%
  • 1985$53.50M—

Cash on Hand values are taken from Biogen's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Cash on Hand at Biogen (BIIB)

According to Biogen's latest reported financial statements, the company's latest reported cash and short-term investments is $4.28B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Biogen (BIIB) most recent annual cash and short-term investments stands at $3.82B (2025) – surged 60.7% year-over-year.

Biogen cash and short-term investments has grown for 2 consecutive years, with a +7.9% compound annual growth rate over 2020–2025 (5 years).

Between 2016 and 2025, Biogen cash and short-term investments declined 22.1%, falling from $4.90B to $3.82B.

$4.90B stands as the all-time-high annual cash and short-term investments, posted in 2016, against a low of $12.60M during 1990.

Biogen Cash on Hand by Year

Biogen Cash on Hand 2025: $3.82B

Biogen cash and short-term investments in 2025 was $3.82B, surged 60.7% from 2024.

Biogen Cash on Hand 2024: $2.38B

2024's cash and short-term investments for Biogen came in at $2.38B, surged 126.2% from 2023.

Biogen Cash on Hand 2023: $1.05B

Biogen posted cash and short-term investments of $1.05B in 2023, plunged 78.5% below 2022.

Biogen Cash on Hand 2022: $4.89B

In 2022, Biogen reported cash and short-term investments of $4.89B, grew 28.7% from 2021.

Biogen Cash on Hand 2021: $3.80B

Biogen cash and short-term investments in 2021 was $3.80B.

See more financial history for Biogen (BIIB).

Sector peers by Cash on Hand

Healthcare peers of Biogen (BIIB), ranked by their latest cash and short-term investments

Frequently asked questions

Biogen (BIIB) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation